How Pharmaceutical-Grade Ketamine Tablet Is Made

When patients take ketamine tablet, the quality, purity, and accuracy of the product they receive depends on where and how it was made. Understanding pharmaceutical manufacturing standards — and how they differ from compounding pharmacy practices — helps patients make informed decisions and ask the right questions of their healthcare providers.

Pharmaceutical Manufacturing vs. Compounding: A Fundamental Distinction

Before examining how ketamine tablet is made, it is important to understand the two distinct manufacturing paradigms in the ketamine space:

Pharmaceutical manufacturing refers to large-scale production by licensed drug manufacturers under FDA oversight and Current Good Manufacturing Practice (cGMP) regulations. The Ketalar (injectable ketamine) you receive in a hospital is made this way.

Compounding refers to small-scale, pharmacy-based preparation of customized medications for individual patients. The vast majority of ketamine tablet tablets, troches, and capsules are made through compounding.

No commercially manufactured, FDA-approved ketamine tablet tablet currently exists, so pharmaceutical-grade manufacturing standards are primarily relevant to:

1. The injectable ketamine used as the source API
2. Emerging pharmaceutical development programs for oral formulations
3. 503B outsourcing facilities operating under FDA cGMP-like standards

Current Good Manufacturing Practice (cGMP)

The foundation of pharmaceutical manufacturing quality is cGMP — a set of regulations enforced by the FDA that establish minimum requirements for manufacturing, processing, and holding pharmaceutical products.

Core cGMP Principles

Personnel: Manufacturing personnel must be qualified, trained, and supervised. Microbiology, chemistry, and quality assurance expertise are required.

Buildings and Facilities: Manufacturing facilities must be designed and maintained to prevent contamination, mix-ups, and errors. Environmental controls (temperature, humidity, air quality) are rigorously maintained.

Equipment: All manufacturing equipment must be qualified, calibrated, and regularly maintained. Equipment that contacts drug products must be constructed of appropriate materials that do not react with or contaminate the drug.

Production and Process Controls: Every step of manufacturing must follow validated, documented procedures. Process controls include in-process testing to ensure the product meets specifications at each stage.

Laboratory Controls: Raw materials, in-process samples, and finished products must be tested against established specifications. Results must be documented and reviewed before any batch is released.

Records and Reports: Comprehensive batch records document every manufacturing step. These records enable traceability and investigation of any problems that occur.

Returned and Salvaged Drug Products: Strict rules govern how returned or potentially compromised products are handled.

How the Active Pharmaceutical Ingredient (API) Is Made

Ketamine hydrochloride — the API used in both injectable and compounded oral products — is manufactured through a multi-step chemical synthesis process. The raw materials are pharmaceutical-grade chemicals sourced from qualified suppliers.

Synthesis Overview

Ketamine is synthesized from cyclohexanone and other precursor chemicals through a sequence of chemical reactions including:

1. Cyclohexanone derivatization to form a key intermediate
2. Rearrangement and ring formation to create the cyclohexamine structure
3. N-methylation to introduce the methylamino group
4. Salt formation with hydrochloric acid to produce ketamine hydrochloride
5. Purification by crystallization or chromatography
6. Drying and milling to achieve specified particle size

The racemic mixture of R- and S-enantiomers is produced by standard synthesis. Esketamine (Spravato) requires an additional resolution step to isolate the S-enantiomer.

Quality Testing of API

Before the API is released for use, it must meet specifications in the official ketamine monograph (United States Pharmacopeia or European Pharmacopoeia). Tests include:

• Identity testing (to confirm the compound is ketamine HCl)
• Assay (to confirm potency within specification, typically 98.0–102.0%)
• Related substances (to quantify impurities and degradation products)
• Residual solvents (to ensure manufacturing solvents are within safe limits)
• Water content
• Optical rotation (to confirm enantiomeric composition)
• Microbial limits (for non-sterile products)

Manufacturing Ketamine Tablet Tablets (Future Commercial Products)

While no commercial ketamine tablet tablet currently exists, pharmaceutical companies developing such products would follow this general process:

Formulation Development

Pharmaceutical scientists design the tablet formulation to achieve target dissolution rates, stability, and bioavailability. Components include:

• Active ingredient: Ketamine HCl at the target dose
• Diluents/fillers: Microcrystalline cellulose, lactose, or mannitol provide bulk
• Binders: Hydroxypropyl methylcellulose (HPMC) or polyvinylpyrrolidone (PVP) hold the tablet together
• Disintegrants: Croscarmellose sodium or sodium starch glycolate promote tablet breakdown in the gut
• Lubricants: Magnesium stearate prevents sticking to equipment
• Coatings: Film coats improve swallowability and may mask the drug's bitter taste

Manufacturing Steps

1. Blending: API and excipients are blended to achieve uniform distribution
2. Granulation: Wet or dry granulation improves flow properties for tableting
3. Tablet compression: The granulate is compressed into tablets using high-speed tablet presses
4. Coating: Film coating is applied in rotating coating pans
5. Inspection: Tablets are inspected for appearance, weight, thickness, and hardness
6. Testing: Samples are tested for dissolution, content uniformity, and stability
7. Packaging: Tablets are packaged in appropriate containers with desiccants if needed

How Compounding Pharmacies Make Ketamine Tablet

Compounding pharmacies follow USP 795 (non-sterile compounding) standards rather than cGMP, but quality compounders implement rigorous internal controls.

Troche Compounding

1. Ketamine HCl is weighed precisely using calibrated balances
2. The API is blended into a molten base (polyethylene glycol or cocoa butter)
3. Flavoring agents are added
4. The mixture is poured into troche molds and allowed to solidify
5. Troches are weighed to verify consistency
6. Beyond-use dating is assigned (typically 30–180 days depending on the base and storage conditions)
7. The product is labeled with all required information

Tablet Compounding

Compounded tablets follow similar steps to pharmaceutical manufacturing but at smaller scale with simplified equipment. Direct compression or small-scale granulation may be used.

Key Differences: Pharma vs. Compounded

What This Means for Patients

Patients should be aware that:

1. The compounded ketamine tablet they receive has not undergone the same level of testing as FDA-approved drugs
2. Quality varies between compounding pharmacies — PCAB accreditation indicates higher standards
3. Asking whether your pharmacy tests potency of their ketamine preparations is reasonable and appropriate
4. Future FDA-approved ketamine tablet products would offer higher manufacturing quality assurance than current compounded alternatives

Understanding manufacturing standards is not about alarmism — the vast majority of PCAB-accredited compounding pharmacies produce quality products. It is about making informed healthcare decisions.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches